Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Clin Biochem. 2021 Oct;96:13-18. doi: 10.1016/j.clinbiochem.2021.06.007. Epub 2021 Jul 1.
Accumulating evidences suggest that immune checkpoints (ICs) inhibit immune response against cancerous cells and promote tumor cell survival. Up-regulation of ICs in tumor microenvironment is reported in patients with colorectal cancer (CRC). Thus, evaluating the peripheral blood expression of ICs may be used as non-invasive biomarkers for diagnosis and prognosis of CRC.
This study included 60 primary and treatment naïve CRC patients along with 15 age and sex matched healthy volunteers as a control group. Total RNA was extracted from peripheral blood samples and gene expression of cytotoxic T lymphocyte antigen-4 (CTLA-4), B and T lymphocyte attenuator (BTLA), T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and Lymphocyte activation gene-3 (LAG-3) was measured by quantitative real time polymerase chain reaction (qRT-PCR). All patients were followed for 12 months to correlate the measured ICs to patients' survival.
The gene expression of CTLA-4, BTLA, TIM-3 and LAG-3 was significantly up-regulated in CRC patients compared to the control group (p < 0.001). Individually, CTLA-4 and BTLA showed 85% sensitivity in discriminating CRC patients from control group (p < 0.001). On the other hand, TIM-3 and LAG-3 expression showed higher sensitivity (93%) for diagnosis of CRC (p < 0.001). Conversely, CTLA-4 or BTLA strongly predicted CRC patients' survival (p < 0.001) compared to TIM-3 (p = 0.018) or LAG-3 (p = 0.035). CTLA-4, BTLA, TIM-3 and LAG-3 were independent prognostic factors of survival after adjustment for age and gender.
The current study provided evidence that blood gene expression of ICs was up-regulated in CRC patients and associated with cancer stage and patients' survival, which highlights the diagnostic and prognostic values of ICs expression in CRC. Further investigations and validations in larger cohorts are required.
越来越多的证据表明,免疫检查点(ICs)抑制了针对癌细胞的免疫反应,并促进了肿瘤细胞的存活。据报道,在结直肠癌(CRC)患者的肿瘤微环境中,ICs 上调。因此,评估外周血中 ICs 的表达可能可作为 CRC 诊断和预后的非侵入性生物标志物。
本研究纳入了 60 名初治的 CRC 患者和 15 名年龄和性别匹配的健康志愿者作为对照组。从外周血样本中提取总 RNA,并通过实时定量聚合酶链反应(qRT-PCR)测量细胞毒性 T 淋巴细胞抗原-4(CTLA-4)、B 和 T 淋巴细胞衰减因子(BTLA)、T 细胞免疫球蛋白和粘蛋白结构域蛋白 3(TIM-3)和淋巴细胞激活基因-3(LAG-3)的基因表达。对所有患者进行了 12 个月的随访,以将所测量的 ICs 与患者的生存情况相关联。
与对照组相比,CRC 患者的 CTLA-4、BTLA、TIM-3 和 LAG-3 的基因表达显著上调(p<0.001)。单独来看,CTLA-4 和 BTLA 在区分 CRC 患者和对照组方面具有 85%的敏感性(p<0.001)。另一方面,TIM-3 和 LAG-3 的表达对 CRC 的诊断具有更高的敏感性(93%)(p<0.001)。相反,与 TIM-3(p=0.018)或 LAG-3(p=0.035)相比,CTLA-4 或 BTLA 可强烈预测 CRC 患者的生存情况(p<0.001)。在调整年龄和性别后,CTLA-4、BTLA、TIM-3 和 LAG-3 是生存的独立预后因素。
本研究提供的证据表明,CRC 患者的外周血 IC 基因表达上调,并与癌症分期和患者的生存相关,这突出了 ICs 表达在 CRC 中的诊断和预后价值。需要在更大的队列中进行进一步的研究和验证。